Actively Recruiting
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
Led by Peking Union Medical College · Updated on 2025-04-16
100
Participants Needed
1
Research Sites
285 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to retrospectively analyze the efficacy and safety of secukinumab combined with surgery in treating moderate to severe HS in real-world clinical practice, providing clinical practioners with real-world evidence in HS treatment.
CONDITIONS
Official Title
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 80 years old with moderate-severe (Hurley II-III) hidradenitis suppurativa
- Diagnosis confirmed by histopathological examination at the hospital's Department of Pathology
- Patients who received secukinumab combined with surgery in the hospital's Department of Dermatologic Surgery
- Patients with complete clinical data and at least one year of follow-up
You will not qualify if you...
- Patients lost to follow-up
- Patients with less than one year of follow-up
- Patients who received additional adjuvant therapy during the follow-up period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science and Peking Union Medical College
Nanjing, Jiangsu, China, 210042
Actively Recruiting
Research Team
Y
Youjun ZHENG
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here